Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Updated Phase 2 lung-cancer data for lifileucel24.6% overall response and 59.1% in a small biomarker-enriched subgroupsparked a sharp selloff and debate over whether the subgroup findings narrow the addressable market and complicate the regulatory path. Some traders view the overall results and enriched response signal as encouraging, while others are concerned about validation, response-duration details, and the planned 2027 filing timeline.

Alphabets quarterly results sparked a sharp selloff, with traders focused on heavy AI infrastructure spending and negative free cash flow alongside slowing Search and advertising growth. The debate centers on whether strong Cloud and Gemini momentum can justify the investment: some see an overreaction and buying opportunity, while others question AI monetization and future returns.

Microsofts fiscal first-quarter results beat expectations, with Azure growth accelerating to 48% and its outlook pointing to further growth; traders welcomed the cloud performance but debated whether heavy AI investment, lower-than-expected reported capex amid capacity delays, and a new bond offering could limit the upside. The initial post-earnings rally faded, with some attributing the pullback to broader weakness in tech and Alphabets results.

Alphabets earnings miss has put the shares under pressure, with traders focused on slowing Search and advertising momentum and heavy AI investment raising concerns about cash flow and returns. Some view the selloff as overdone given strong Cloud growth, while bears question whether AI competition and rising spending will erode profitability.

Oracles investor-day outlookmapping a path to positive free cash flow, limiting additional financing, and forecasting strong long-term growthhelped ease concerns about the cost of its AI data-center expansion and drove a sharp rally. Traders welcomed the greater financial clarity, while skeptics questioned whether management can deliver and warned that debt, execution risks, and weakness elsewhere in tech could pressure the shares.

ServiceNows quarterly earnings miss and softer outlook for contracted-revenue growth triggered a sharp selloff, overshadowing revenue growth and raised AI targets. Traders are split between calling the reaction an overreaction and seeing it as a warning about slowing growth, elevated expectations, and AI-related risks to enterprise software.

Norwegians quarterly results beat expectations and the company raised its full-year outlook, driving a relief rally after prolonged weakness and analyst downgrades. Traders are celebrating the results and speculating about short covering, while others remain cautious about yields, debt, fuel costs, and whether management can sustain the improvement.

Reports that Marvell is in advanced talks to acquire Lumentum have driven discussion, though no deal is final. Traders debate the strategic value of adding scarce optical components for AI data centers against financing, dilution and integration risks; some see long-term benefits while others view the potential deal as a near-term negative.

Lillys strong third-quarter results and higher full-year revenue outlook, driven by demand for Mounjaro and Zepbound, are drawing bullish attention and fueling discussion of continued GLP-1 growth. Some traders caution that profit guidance was trimmed amid deal-related charges, Foundayos launch is facing questions, and valuation is demanding; retatrutides trial results add to the pipeline optimism.

SELLASs Phase 3 REGAL AML trial reached its prespecified 80th event, triggering final analysis ahead of preliminary topline results expected this quarter; the update did not disclose whether GPS improved survival. The milestone was followed by a sharp selloff, with traders debating whether it was a shakeout or profit-taking while others stressed the binary risk ahead of the data.